• ImmunityBio, Inc. recently reported preliminary first-quarter 2026 net product revenue of approximately US$44.2 million, indicating an approximately 168% year-over-year increase compared with the same period in 2025.
• This sharp revenue acceleration puts fresh focus on how quickly ANKTIVA and the broader portfolio are converting clinical progress into commercial uptake.
• Next, we’ll examine how this sharp jump in preliminary net product revenue may influence ImmunityBio’s previously outlined investment narrative.

The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, you need to believe ANKTIVA can grow from a single approved bladder cancer use into a broader, multi indication immunotherapy platform, while the company narrows sizeable losses. The sharp jump to about US$44.2 million in preliminary Q1 2026 net product revenue highlights how quickly existing approvals can translate into sales, but it does not remove the near term risk that progress on new indications or regulatory decisions might be slower or more complex than hoped.

The most relevant recent development alongside this revenue update is the European Commission’s conditional marketing authorization for ANKTIVA plus BCG in NMIBC CIS with or without papillary tumors across 33 countries. That approval, combined with the Accord Healthcare partnership in the EU, frames Q1’s revenue strength within a broader rollout that could influence near term revenue catalysts, even as execution, reimbursement decisions, and physician uptake remain key variables.

Yet this early revenue surge sits alongside regulatory scrutiny and commercialization risks that investors should be aware of if ANKTIVA uptake or label expansion does not progress as...

ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and an earnings increase of about $787 million from -$351.4 million today.

Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 65% upside to its current price.

Exploring Other Perspectives

Before this latest revenue jump, the most optimistic analysts were already penciling in about US$1.6 billion of revenue and roughly US$672 million of earnings by 2029, which is far more bullish than the baseline narrative and assumes ImmunityBio overcomes capital needs and pipeline execution risks more smoothly than consensus expects.

Explore 10 other fair value estimates on ImmunityBio - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Contemplating Other Strategies?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.